117 related articles for article (PubMed ID: 19889941)
1. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
Cui C; Carbis R; An SJ; Jang H; Czerkinsky C; Szu SC; Clemens JD
Clin Vaccine Immunol; 2010 Jan; 17(1):73-9. PubMed ID: 19889941
[TBL] [Abstract][Full Text] [Related]
2. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
Kossaczka Z; Lin FY; Ho VA; Thuy NT; Van Bay P; Thanh TC; Khiem HB; Trach DD; Karpas A; Hunt S; Bryla DA; Schneerson R; Robbins JB; Szu SC
Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
[TBL] [Abstract][Full Text] [Related]
4. The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi.
Arcuri M; Di Benedetto R; Cunningham AF; Saul A; MacLennan CA; Micoli F
PLoS One; 2017; 12(12):e0189100. PubMed ID: 29287062
[TBL] [Abstract][Full Text] [Related]
5. Development of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharide.
Staats HF; Kirwan SM; Whisnant CC; Stephenson JL; Wagener DK; Majumder PP
Clin Vaccine Immunol; 2010 Mar; 17(3):412-9. PubMed ID: 20107010
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of typhoid vaccines against culture-confirmed Salmonella Typhi in typhoid endemic countries: a systematic review and meta-analysis.
Batool R; Qamar ZH; Salam RA; Yousafzai MT; Ashorn P; Qamar FN
Lancet Glob Health; 2024 Apr; 12(4):e589-e598. PubMed ID: 38485426
[TBL] [Abstract][Full Text] [Related]
7. A novel Vi-diphtheria toxoid typhoid conjugate vaccine is safe and can induce immunogenicity in healthy Indonesian children 2-11 years: a phase II preliminary report.
Medise BE; Soedjatmiko S; Gunardi H; Sekartini R; Satari HI; Hadinegoro SR; Wirahmadi A; Puspita M; Sari RM; Yang JS; Sil A; Sahastrabuddhe S; Bachtiar NS
BMC Pediatr; 2020 Oct; 20(1):480. PubMed ID: 33059607
[TBL] [Abstract][Full Text] [Related]
8. Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG.
Rijpkema S; Hockley J; Logan A; Rigsby P; Atkinson E; Jin C; Goldblatt D; Liang H; Bachtiar NS; Yang JS; Goel A; Ramasamy V; Pasetti MF; Pollard AJ;
Biologicals; 2018 Nov; 56():29-38. PubMed ID: 30201529
[TBL] [Abstract][Full Text] [Related]
9. A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines.
Alugupalli KR
Front Immunol; 2024; 15():1383476. PubMed ID: 38799439
[TBL] [Abstract][Full Text] [Related]
10. Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi.
Acevedo R; Callicó A; Aranguren Y; Zayas C; Valdés Y; Pérez O; García L; Ferro VA; Pérez JL
BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S10. PubMed ID: 23458379
[TBL] [Abstract][Full Text] [Related]
11. Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses.
Jossi SE; Arcuri M; Alshayea A; Persaud RR; Marcial-Juárez E; Palmieri E; Di Benedetto R; Pérez-Toledo M; Pillaye J; Channell WM; Schager AE; Lamerton RE; Cook CN; Goodall M; Haneda T; Bäumler AJ; Jackson-Jones LH; Toellner KM; MacLennan CA; Henderson IR; Micoli F; Cunningham AF
Front Immunol; 2023; 14():1139329. PubMed ID: 37033932
[TBL] [Abstract][Full Text] [Related]
12. Vi antigen expression in Salmonella enterica serovar Typhi clinical isolates from Pakistan.
Wain J; House D; Zafar A; Baker S; Nair S; Kidgell C; Bhutta Z; Dougan G; Hasan R
J Clin Microbiol; 2005 Mar; 43(3):1158-65. PubMed ID: 15750077
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam.
Konadu EY; Lin FY; Hó VA; Thuy NT; Van Bay P; Thanh TC; Khiem HB; Trach DD; Karpas AB; Li J; Bryla DA; Robbins JB; Szu SC
Infect Immun; 2000 Mar; 68(3):1529-34. PubMed ID: 10678970
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of Vi-diphtheria toxoid typhoid conjugate vaccine among children below 2 years: a systematic review and meta-analysis.
Mohamed Taha A; Abouelmagd K; Mahmoud AM; Elkasaby MH; Nguyen D; Ahmed R; Patel P; Bonilla-Aldana DK; Luna C; Rodriguez-Morales AJ
Front Microbiol; 2024; 15():1385834. PubMed ID: 38646637
[TBL] [Abstract][Full Text] [Related]
15. Glycoconjugate vaccines against
Bazhenova A; Gao F; Bolgiano B; Harding SE
Biophys Rev; 2021 Apr; 13(2):221-246. PubMed ID: 33868505
[TBL] [Abstract][Full Text] [Related]
16. Immune suppression induced by Vi capsular polysaccharide is overcome by Vi-DT conjugate vaccine.
An SJ; Yoon YK; Kothari S; Kim DR; Kim JA; Kothari N; Lee E; Park TH; Carbis R
Vaccine; 2012 Feb; 30(6):1023-8. PubMed ID: 22192846
[TBL] [Abstract][Full Text] [Related]
17. Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.
van Damme P; Kafeja F; Anemona A; Basile V; Hilbert AK; De Coster I; Rondini S; Micoli F; Qasim Khan RM; Marchetti E; Di Cioccio V; Saul A; Martin LB; Podda A
PLoS One; 2011; 6(9):e25398. PubMed ID: 21980445
[TBL] [Abstract][Full Text] [Related]
18. Testing a Recombinant Form of Tetanus Toxoid as a Carrier Protein for Glycoconjugate Vaccines.
Oldrini D; Di Benedetto R; Carducci M; De Simone D; Massai L; Alfini R; Galli B; Brunelli B; Przedpelski A; Barbieri JT; Rossi O; Giannelli C; Rappuoli R; Berti F; Micoli F
Vaccines (Basel); 2023 Nov; 11(12):. PubMed ID: 38140177
[TBL] [Abstract][Full Text] [Related]
19. Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines.
Micoli F; Stefanetti G; MacLennan CA
Front Mol Biosci; 2023; 10():1201693. PubMed ID: 37261327
[TBL] [Abstract][Full Text] [Related]
20. Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose.
Capeding MR; Tadesse BT; Sil A; Alberto E; Kim DR; Park EL; Park JY; Yang JS; Eluru JR; Jo SK; Kim H; Yang SY; Ryu JH; Park H; Shin JH; Lee Y; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
NPJ Vaccines; 2022 Jan; 7(1):12. PubMed ID: 35087084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
